Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ian Haydock

Tokyo, Japan
Ian is head of pharma news content for the Asia-Pacific area and has been covering the region for more than 20 years as an editor for Scrip and more recently as managing editor of PharmAsia News. He has a long background in Asia, having grown up in Hong Kong, and a particular interest in regional regulatory harmonization and trade initiatives and the development of the Japanese pharma sector. Ian lives in Tokyo with his wife and two sons.

Latest From Ian Haydock

Daiichi's Novel EZH Candidate Progresses In New Consortium Trial

Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.

Clinical Trials Research & Development

Quick Listen: Scrip’s Five Must-Know Things

A resolution in a long-running patent dispute, expansion of coronavirus vaccine production, drug development trends over the past decade, hematological malignancies in a clinical trial, and the last instalment in the Scrip Asks series all feature in this week's podcast version of Scrip's Five Must-Know Things.

Coronavirus COVID-19 Clinical Trials

Japan Pricing Environment ‘Highly Unpredictable’: PhRMA

US research-based association says move to annual drug repricing undermines country’s recent efforts to support innovation and again calls for inclusive discussions around broad health system reforms to create funding headroom.

Japan Policy

Padcev Positioned For Urothelial Cancer Expansion

First-in-class ADC set for expanded use on the back of additional data, but analysts see first-line setting as probably the main growth driver.

Research & Development Clinical Trials

Japan Approves First Coronavirus Vaccine But Hurdles Ahead?

Japanese authorities have issued their first approval for a coronavirus vaccine, to Pfizer/BioNTech’s mRNA product Comirnaty, but public vaccine hesitancy and logistics challenges could be hurdles to achieving high administration rates and effective herd immunity.

Japan Coronavirus COVID-19

Quick Listen: Scrip’s Five Must-Know Things

Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip's worldwide team, in this podcast version of Five Must-Know Things. 

Approvals Business Strategies
See All
UsernamePublicRestriction

Register